Refametinib

Drug Profile

Refametinib

Alternative Names: AR-119; BAY-86-9766; RDEA-119; VRX-119

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Ardea Biosciences; Bayer HealthCare; Samsung Medical Center
  • Class Aniline compounds; Anti-inflammatories; Antineoplastics; Small molecules; Sulfonamides
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Hepatocellular carcinoma
  • Phase I/II Pancreatic cancer; Solid tumours
  • Discontinued Inflammation

Most Recent Events

  • 08 Feb 2017 Bayer completes a phase II trial in hepatocellular carcinoma (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease) in USA, Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Spain, United Kingdom, Hong Kong, Israel, South Korea, Singapore, Turkey, Taiwan, Thailand, China, Japan, New Zealand, Switzerland (NCT01915602)
  • 13 Oct 2016 Samsung Medical Center completes a phase II trial in Biliary cancer (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in South Korea (PO) (NCT02346032)
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top